As obesity is known to increase the risk of cardiovascular disease, including HF, therefore, anti-obesity interventions like tirzepatide may have cardioprotective effects [101]
Two GLP-1R agonists have been approved in the United States to treat obesity: semaglutide and LIR, both of which are injected subcutaneously
A major clinical trial showed patients taking oral semaglutide lost approximately 35% of their body weight over 26 weeks, with some individuals achieving greater reductions through consistent diet and exercise adherence
[32] Because stomach emptying is the testing process's rate-limiting step, the amount of 13CO2 present in an exhaled breath test represents gastric emptying
This type is often less responsive to corticosteroids and may require alternative treatment options
Glutathione Lene Ka Sahi Samay Subah Ya Raat